Health
Europe Struggles to Meet Tuberculosis Targets Amid Rising Drug Resistance
Tuberculosis remains a public health issue in Europe as the region falls behind elimination targets, according to a new report by the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC). The report warns that one in five cases goes undiagnosed, while drug resistance continues to exceed global averages.
Although the overall number of TB cases has declined, progress toward elimination remains insufficient. Tuberculosis, an infectious disease spread when an individual with pulmonary TB expels bacteria through coughing, is the leading cause of death from a single infectious agent worldwide. Common symptoms include a persistent cough lasting more than two weeks, fever, night sweats, and weight loss.
Across the WHO European Region, which covers 53 countries in Europe and Central Asia, TB incidence has fallen by 39 percent since 2015, and deaths have dropped by 49 percent. These figures fall short of the WHO’s End TB Strategy 2025 milestones of 50 percent reduction in cases and 75 percent reduction in deaths.
Within the European Union, cases have decreased by 33 percent and deaths by 17 percent, insufficient to meet the 2030 targets. Health authorities note this gap has led to thousands of preventable infections and fatalities. In 2024, more than 160,000 newly diagnosed TB cases were reported, while the estimated actual number of cases was 204,000, meaning only 79 percent were officially notified.
Hans Kluge, WHO Regional Director for Europe, said undiagnosed cases represent missed opportunities to treat patients earlier and curb transmission. “By investing in rapid diagnosis, shorter all-oral treatment regimens and stronger follow-up, countries can reach more people earlier, improve outcomes and put us back on track toward our targets,” he said. Delayed diagnosis increases treatment difficulty and heightens the risk of spreading the disease.
Drug-resistant tuberculosis remains a major challenge. Multi-drug resistant TB among new and previously treated cases stands at 23 percent and 51 percent, respectively, far above the global averages of 3.2 percent and 16 percent. Standard treatment for non-resistant TB typically lasts six months with success rates above 85 percent, but resistant variants require longer, more complex regimens with lower success rates.
Most European countries now report low TB incidence, with notification rates below 10 per 100,000. The disease mainly affects vulnerable populations, including migrants, prison inmates, and people with HIV co-infections. Ralf Otto-Knapp of the German Central Committee against Tuberculosis warned that lower overall case numbers in Western Europe have led to decreased attention, making it harder to combat multidrug-resistant TB. “We must strengthen treatment and prevention services, ensure easy access to new medicines and foster cross-border cooperation,” he said.
The report underscores that without urgent action on diagnosis, treatment, and drug resistance, Europe risks falling further behind its TB elimination goals, putting vulnerable communities at heightened risk.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
